Ayse Nilhan ATSÜ, Görkem ORUC ADALI, Nazlı CAF, Zafer TÜRKOGLU

Evaluation of Demographic and Clinical Data of Herpes Zoster Patients Admitted To Tertiary Referral Dermatology Clinic During COVID-19 Pandemic

Background: Herpes zoster infection (shingles) occurs due to reactivation of the varicella zoster virus (VZV) usually contracted during childhood. Dermatomal involvement is characterized by vesicular rash. Symptoms such as pain and itching are usually present. Complications may be life-threatening and/or result with sequelae. Psychogenic factors and/or other underlying systemic diseases may provoke reactivation of VZV. Coronavirus disease (COVID-19) infection is one such factor. Objectives: The aim of this study is to evaluate the demographic and clinical data collected from patients admitted to our tertiary referral medical center and diagnosed with herpes zoster during the COVID-19 pandemic. Methods: Six hundred and sixty-one patients admitted to our hospital and diagnosed with herpes zoster between October 2020 and October 2021 were included in the cross-sectional retrospective study. Results: The age range was between 1 and 90, and the mean age was 50.4±19.9 years. Fifty percent were female and 50% were male. Complications were found in 62% of the patients, and 54% had postherpetic neuralgia. A history of an additional comorbidity was found in 79% of the patients. It was observed that 10% of the patients were hospitalized, and their mean age was 66.26±14.4 years. Three percent of the patients had an association with COVID-19 vaccine/infection. Conclusion: Our study is unique because it includes both pediatric and adult patients. Also significant for providing one-year demographic data for shingles during the COVID-19 era.

Keywords:

Acyclovir, COVID-19, herpes zoster, neuralgia,

PDF

___

1. Schmader K. Herpes Zoster. Clin Geriatr Med. 2016; 32(3): 539–53.
2. Dayan RR, Peleg R. Herpes zoster–typical and atypical presentations. Postgrad Med. 2017; 129(6): 567–71.
3. Weinberg JM. Herpes zoster: Epidemiology, natural history, and common complications. J Am Acad Dermatol. 2007; 57(6 SUPPL.): 130–5.
4. Elsaie ML, Youssef EA, Nada HA. Herpes zoster might be an indicator for latent COVID 19 infection. Dermatol Ther. 2020; 33(4).
5. Elsam Koshy, Lu Mengting, Hanasha Kumar WJ. Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. Indian J Dermatol Venereol Leprol. 2018; 84(3): 251–62.
6. Chesser AK, Keene Woods N, Smothers K, Rogers N. Health Literacy and Older Adults. GerontolGeriatr Med. 2016; 2: 233372141663049.
7. Ali KBM. Epidemio-clinical study of Herpes Zoster in Erbil City. Zanco J Med Sci. 2010;14(1):85–90.
8. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26–33.
9. Castle SC, Uyemura K, Rafi A, Akande O, Makinodan T. Comorbidity is a better predictor of impaired immunity than chronological age in older adults. J Am Geriatr Soc. 2005;53(9):1565–9.
10. Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 than Women? SN ComprClin Med. 2020;2(7):874–6.
11. Nozomu Toyama, Kimiyasu Shirakiand M of the S of the MP, Dermatologists. Epidemiology of Herpes Zoster and Its Relationship to Varicella in Japan: A 10- Year Survey of 48,388 Herpes Zoster Cases in Miyazaki Prefecture. J Med Virol. 2009;81(12):2053–8.
12. James WD, Elston D, Treat J, Rosenbach M, Neuhaus IM. Andrews’ Diseases of the Skin. 13th Editi. Elsevier Inc.; 2020. 249–250.
13. Bader MS. Herpes zoster: diagnostic, therapeutic, and preventive approaches. Postgrad Med. 2013;125(5):78–91.
14. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: Towards a global perspective. BMJ Open. 2014;4(6).
15. Chen X, Hovanesian V, Naqvi S, et al. Systemic infusions of anti-interleukin-1β neutralizing antibodies reduce short-term brain injury after cerebral ischemia in the ovine fetus. Brain Behav Immun. 2018;67:24–35.
16. S A J Schmidt, A Mor, H C Schønheyder, H T Sørensen, O M Dekkers DC-F. Herpes zoster as a marker of occult cancer: A systematic review and meta-analysi. J Infect. 2017;74(3):215–35.
17. Yıldız Çeltek N, Ünlü U. Evaluation of zona zoster cases occuring in cancer- diagnosed patients. Turkish J Fam Med Prim Care. 2020;14(4):646–50.
18. Yavaşoğlı İ., Arslan E., GökM.R.K. Erişkin Zona: Olgu Serisi ve Derleme. Uludağ Üniversitesi Tıp Fakültesi Derg. 2008;34(3):123–5.
19. Soyuncu S, Berk Y, Eken C, Gulen B, Oktay C. Herpes zoster as a useful clinical marker of underlying cell mediated immune disorders. Ann Acad Med Singapore. 2009;38(2):136–8.